Policy & Regulation
BerGenBio closes recruitment for COVID-19 trial
4 March 2021 -

Norwegian biopharmaceutical company BerGenBio ASA (OSE:BGBIO) has closed recruitment for a trial that will assess the efficacy and safety of bemcentinib for the treatment of hospitalised COVID-19 patients in South Africa and India, the company said on Thursday.

A total of 114 out of the target 120 hospitalised COVID-19 patients were recruited into the company-sponsored, randomised Phase II clinical trial (BGBC020) across five sites in South Africa and seven sites in India. Of these patients, 56 received bemcentinib (as monotherapy or in combination with standard of care medication) and 58 in a control group received standard of care treatment only.

The trial protocol permits co-administration with other medicines recommended for treatment of COVID-19, including remdesivir and dexamethasone.

Bemcentinib (formerly known as BGB324), is a potential first-in-class, potent and highly selective AXL inhibitor which is administered as an oral capsule and taken once per day.

Top-line clinical results are expected around the end of the first quarter of 2021.



Related Headlines